The near-term future for the Merck Group and Merck Serono.

• Read more

Darmstadt, Germany, May 15, 2012 – Merck announced today details of its planned cost efficiencies for Merck Serono and introduced mid-term financial targets at its Capital Markets Day in Darmstadt. These details are part of the Group’s previously announced plan to transform the company through a comprehensive efficiency program.

• More IR News

Darmstadt, Germany, May 9, 2012 – Merck announced today results from an interim analysis of the Phase III clinical trial PETACC-8. The study investigated the potential clinical utility of Erbitux® (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor. The pre-specified interim analysis of the study did not support benefit in disease free survival for patients given Erbitux plus standard chemotherapy (FOLFOX 4) compared with patients treated with FOLFOX 4 alone. Therefore this interim analysis does not support the use of Erbitux for the adjuvant treatment of stage III colon cancer in this setting. PETACC-8 is a randomized, controlled, multinational European trial sponsored and coordinated by the Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France.

• More IR News

May 15, 2012 – "Merck delivered a reasonable operating performance in the face of a difficult year-over-year comparison,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck. “During the first quarter, we kicked off our efficiency program and announced the first planned initiatives as part of this transformation. Our focus during 2012 will be to deliver a solid operational performance while bringing our cost structure more in line with our competitors and peers.”

• Press- and Analyst Conferences
• Read the Online Quarterly Financial Report Q1 2012 online
• Download the full PDF version